• Males and Females, age ≥18 years and ≤75 years;

• Histologically or cytologically confirmed primary non-squamous NSCLC:

‣ Stage IB, II, IIIA or IIIB (N2) NSCLC (per AJCC8);

⁃ No administration of any anti-NSCLC therapy in the pre-operative period;

⁃ Be able to undergo the radical resection; Pulmonary function capacity capable of tolerating the proposed lung resection according to the surgeon.

• Participants without EGFR mutations or ALK translocation;

• At least 1 measurable lesion per RECISIT v1.1;

• Eastern Cooperative Oncology Group (ECOG) Performance Status score of 0-1;

• Adequate organ function confirmed at screening period.